Home/Filings/4/0001415889-19-000624

4//SEC Filing

Pontifax Management 4 G.P. (2015) Ltd. 4

Accession 0001415889-19-000624

CIK 0001035354other

View on SEC.gov Company Profile

Filed

May 28, 8:00 PM ET

Accepted

May 29, 5:15 PM ET

Size

33.0 KB

Accession

0001415889-19-000624

Insider Transaction Report

Form 4

Period: 2019-05-29

Eloxx Pharmaceuticals, Inc.ELOX

Pontifax (Cayman) IV L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax (China) IV L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax Management 4 G.P. (2015) Ltd.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax IV GP L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax (Israel) IV, L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax Management III G.P. (2011) Ltd.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax Management Fund III L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax (Cayman) III, L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Pontifax (Israel) III, L.P.

10% Owner

Transactions

Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)
Award
Stock Option (Right to Buy)
2019-05-29+20,000→ 20,000 total(indirect: See Footnote)
Exercise: $9.02Exp: 2029-05-29→ Common Stock (20,000 underlying)

Footnotes (3)

[F1]One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
[F2]The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, "Pontifax"). Pontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P. Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P. Mr. Kariv will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.
[F3]The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.

Documents

2 files

Issuer

Eloxx Pharmaceuticals, Inc.

CIK 0001035354

→

Entity typeother

IncorporatedIsrael

Related Parties

filerCIK 0001726334

Filing Metadata

Form type: 4
Filed: May 28, 8:00 PM ET
Accepted: May 29, 5:15 PM ET
Size: 33.0 KB

View on SEC.gov